Anagenex
A drug discovery company pairing large-scale data generation with proprietary artificial intelligence (AI) to discover the next generation of small molecule medicines.
Anagenex's precision small molecule discovery platform leverages AI to design and custom chemistry to synthesize 100M target-specific for testing in two weeks, creating a virtuous cycle between real lab experiments and computational tools.
The company’s pipeline is focused on synthetic lethal oncology.
Latest Anagenex News & Features
4 March 2024
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze